Site Map

• Home
• About
• Participating Companies
  • Amgen Inc.
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • EMD Serono, Inc.
  • Genentech
  • Kyowa Hakko Kirin Co., Ltd.
  • SpringWorks Therapeutics, Inc.
  • Syntrix Biosystems, Inc.
  • Turning Point Therapeutics
  • Xcovery Holding Company LLC
• Available Agents
  • Abemaciclib
  • Adavosertib
  • Alectinib
  • Atezolizumab
  • Avelumab
  • Bevacizumab
  • Blinatumomab
  • Capivasertib
  • Cediranib
  • Ceralasertib
  • Cobimetinib
  • Durvalumab
  • Elzovantinib
  • Ensartinib
  • Ipilimumab
  • Larotrectinib
  • Mirdametinib
  • Mogamulizumab
  • Nirogacestat
  • Nivolumab
  • Obinutuzumab
  • Olaparib
  • Pertuzumab
  • Regorafenib
  • Repotrectinib
  • Savolitinib
  • Selpercatinib
  • SX-682
  • Talimogene laherparepvec
  • Trastuzumab
  • Tremelimumab
  • Vemurafenib
• Information for Investigators
  • Access Agents
  • PI/Institution Eligibility
• Information for Companies